Frontiers in Clinical Drug Research – Anti-Cancer Agents

Bentham Science has recently launched the new volume of the book, Frontiers in Clinical Drug Research – Anti-Cancer Agents. Frontiers in Clinical Drug Research – Anti-Cancer Agents is a book series essential for pharmaceutical scientists, postgraduate students and researchers seeking the latest, critical information for developing clinical trials and drafting research plans in anti-cancer research. Reviews in this volume are written by experts in medical oncology and clinical trials research, and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers.

The first chapter covers information on AML (Acute myeloid leukemia). Irrespective of the diverse modes of treatment, the prognosis and clinical response of AML (Acute myeloid leukemia) remain low as the conventional modes of treatment, including cytarabine and anthracycline have their limitations. Additionally, chemotherapy-induced cytotoxicity triggers the remission, thus most of AML patients succumb to relapse. The monotherapy is also not helping much due to the rapid growth of AML, while an insufficient period of time is a major barrier in immunotherapy. Therefore, the current focus has been on combination therapy, with different agents, possibly because chemotherapy for AML is associated with infection, inflammation and could be rather toxic when combined with immunotherapy.

Further the book sheds light on therapies for prostate cancer. Prostate Cancer (PCa) is a major global health burden with alarming epidemiological indices. Research advances in this area have revealed complex molecular aspects associated with the disease, thus necessitating the novel development of diagnostic methods and therapeutic strategies. The main molecular target is the androgen receptor (AR), which is involved in both normal development and malignant transformation. However, many patients become resistant to conventional treatments, and the disease progresses to a castration-resistant stage (CRPC) in which tumor aggressiveness is driven by a constitutive activation of AR signaling. Tremendous effort has been made for elucidating CRPC and chemoresistance.

It also covers research on the human genome sequencing has revealing the complex nature of the human proteome. Researchers have been focused on mapping the proteome to find the right target for drug design. Inhibition of target proteins may be complemented by redundant forms of the proteins in the pathogenesis of diseases. Therefore, it is important to determine key proteins and their coordinating and/or cooperating partner proteins in protein pathways to design innovative chemotherapeutics. Computational and experimental studies indicated that approximately 200.000 protein-protein interactions (PPIs) have been predicted, with only about 8% identified in humans. PPIs play key roles in many important cellular processes, and especially their up-regulation is closely associated with each step of the tumurogenesis in cancer cells.

###

To get the book, please visit:

https:/

/

bit.

ly/

330RpnB